Skip to main navigation

About
R&D
Pipeline
Investors & Media
Careers

Investors & Media

Overview
News
Events & Presentations
Annual Reports
Stock Information
- Stock Quote & Chart
- Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
- FAQs
- Investor Contact

News

Year

August 29, 2020

NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study

August 18, 2020

NGM Bio Announces Oral Plenary Presentation of 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Patients with NASH at The Digital International Liver Congress™ (ILC) 2020

August 12, 2020

NGM Bio Provides Business Highlights and Reports Second Quarter 2020 Financial Results

July 31, 2020

NGM Bio to Present at Two Upcoming Investor Conferences

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 4 of 16

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Toolkit

© 2020 NGM Biopharmaceuticals.

All Rights Reserved.

Privacy Policy.

Top